Biliary atresia-specific deciduous pulp stem cells feature biliary deficiency.
Bile duct regeneration
Biliary atresia
Patient-derived human deciduous pulp stem cells
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
22 11 2021
22 11 2021
Historique:
received:
16
09
2021
accepted:
30
10
2021
entrez:
23
11
2021
pubmed:
24
11
2021
medline:
24
3
2022
Statut:
epublish
Résumé
Biliary atresia (BA) is a severe hepatobiliary disease in infants that ultimately results in hepatic failure; however, its pathological mechanism is poorly elucidated. Current surgical options, including Kasai hepatoportoenterostomy and orthotopic liver organ transplantations, are palliative; thus, innovation in BA therapy is urgent. To examine whether BA-specific post-natal stem cells are feasible for autologous cell source for BA treatment, we isolated from human exfoliated deciduous teeth, namely BA-SHED, using a standard colony-forming unit fibroblast (CFU-F) method and compared characteristics as mesenchymal stem cells (MSCs) to healthy donor-derived control SHED, Cont-SHED. BA-SHED and Cont-SHED were intrasplenically transplanted into chronic carbon tetrachloride (CCl BA-SHED formed CFU-F, expressed MSC surface markers, and exhibited in vitro mesenchymal multipotency similar to Cont-SHED. BA-SHED showed less in vitro hepatogenic potency than Cont-SHED. Cont-SHED represented in vivo bile drainage function and KRT19-positive biliary regeneration in chronic carbon tetrachloride-induced liver fibrosis model mice. BA-SHED failed to show in vivo biliary potency and bile drainage function compared to Cont-SHED. These findings indicate that BA-SHED are not feasible source for BA treatment, because BA-SHED may epigenetically modify the underlying prenatal and perinatal BA environments. In conclusion, these findings suggest that BA-SHED-based studies may provide a platform for understanding the underlying molecular mechanisms of BA development and innovative novel modalities in BA research and treatment.
Sections du résumé
BACKGROUND
Biliary atresia (BA) is a severe hepatobiliary disease in infants that ultimately results in hepatic failure; however, its pathological mechanism is poorly elucidated. Current surgical options, including Kasai hepatoportoenterostomy and orthotopic liver organ transplantations, are palliative; thus, innovation in BA therapy is urgent.
METHODS
To examine whether BA-specific post-natal stem cells are feasible for autologous cell source for BA treatment, we isolated from human exfoliated deciduous teeth, namely BA-SHED, using a standard colony-forming unit fibroblast (CFU-F) method and compared characteristics as mesenchymal stem cells (MSCs) to healthy donor-derived control SHED, Cont-SHED. BA-SHED and Cont-SHED were intrasplenically transplanted into chronic carbon tetrachloride (CCl
RESULTS
BA-SHED formed CFU-F, expressed MSC surface markers, and exhibited in vitro mesenchymal multipotency similar to Cont-SHED. BA-SHED showed less in vitro hepatogenic potency than Cont-SHED. Cont-SHED represented in vivo bile drainage function and KRT19-positive biliary regeneration in chronic carbon tetrachloride-induced liver fibrosis model mice. BA-SHED failed to show in vivo biliary potency and bile drainage function compared to Cont-SHED.
CONCLUSION
These findings indicate that BA-SHED are not feasible source for BA treatment, because BA-SHED may epigenetically modify the underlying prenatal and perinatal BA environments. In conclusion, these findings suggest that BA-SHED-based studies may provide a platform for understanding the underlying molecular mechanisms of BA development and innovative novel modalities in BA research and treatment.
Identifiants
pubmed: 34809720
doi: 10.1186/s13287-021-02652-8
pii: 10.1186/s13287-021-02652-8
pmc: PMC8607730
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
582Informations de copyright
© 2021. The Author(s).
Références
Cell Stem Cell. 2015 Mar 5;16(3):269-74
pubmed: 25732245
Genes Dev. 2013 Jan 15;27(2):169-81
pubmed: 23322300
Pediatr Res. 2011 Dec;70(6):555-9
pubmed: 21857377
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5807-12
pubmed: 12716973
Semin Pediatr Surg. 2020 Aug;29(4):150940
pubmed: 32861444
Biochem Biophys Res Commun. 2012 Jan 20;417(3):986-90
pubmed: 22206678
PLoS One. 2014 Jan 21;9(1):e84182
pubmed: 24465395
J Pediatr Gastroenterol Nutr. 2019 Jan;68(1):56-63
pubmed: 30358741
Sci Rep. 2015 Oct 12;5:14989
pubmed: 26456005
Sci Rep. 2019 Feb 7;9(1):1535
pubmed: 30733544
Nat Biotechnol. 2015 Aug;33(8):853-61
pubmed: 26167630
Stem Cell Res Ther. 2021 Jan 13;12(1):57
pubmed: 33436050
Nat Genet. 1997 Jul;16(3):235-42
pubmed: 9207787
Sci Transl Med. 2018 Aug 22;10(455):
pubmed: 30135248
Stem Cell Res. 2017 Oct;24:25-28
pubmed: 29034890
Nat Genet. 1997 Jul;16(3):243-51
pubmed: 9207788
Stem Cell Reports. 2013 Sep 26;1(4):283-92
pubmed: 24319664
Stem Cell Res Ther. 2010 Mar 15;1(1):5
pubmed: 20504286
Liver Transpl. 2017 Jan;23(1):96-109
pubmed: 27650268
J Hepatol. 2016 Sep;65(3):631-42
pubmed: 27164551
Expert Rev Gastroenterol Hepatol. 2020 Mar;14(3):185-196
pubmed: 32098516
Exp Hematol. 1974;2(2):83-92
pubmed: 4455512
Dig Med Res. 2020 Dec;3:
pubmed: 33615212
Stem Cell Res Ther. 2015 Sep 10;6:171
pubmed: 26358689
Stem Cell Res Ther. 2020 Mar 25;11(1):134
pubmed: 32213198
Cell Rep. 2013 Mar 28;3(3):646-50
pubmed: 23499447
EMBO J. 1998 Sep 1;17(17):4905-8
pubmed: 9724627
Oral Dis. 2018 Jul;24(5):809-819
pubmed: 29316063
Hepatology. 2011 Mar;53(3):905-14
pubmed: 21319190
Stem Cell Res. 2020 Jun 29;47:101900
pubmed: 32622343
Pediatrics. 2011 Dec;128(6):e1428-33
pubmed: 22106076
Surg Today. 2019 Apr;49(4):316-322
pubmed: 30834983